NetworkNewsBreaks – Stemline Therapeutics, Inc. (NASDAQ: STML) Successfully Closes Public Offering Totaling $59.6M
Stemline Therapeutics (NASDAQ: STML) recently announced the closing of an underwritten public offering of 4,255,000 shares of its common stock, which includes the sale of an additional 555,000 shares of common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were sold at a price of $14.00 per share, bringing the company’s total gross proceeds to $59,570,000 before deducting underwriting discounts, commissions and other offering expenses. Stemline intends to use the net proceeds from this offering for clinical development, regulatory, manufacturing and potentially commercial activities regarding its clinical candidates as well as other…







